U.S. markets closed

REGENXBIO Inc. (RGNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
40.91+0.93 (+2.33%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close39.98
Open40.10
Bid26.56 x 900
Ask46.27 x 800
Day's Range38.97 - 41.27
52 Week Range20.03 - 50.26
Volume390,956
Avg. Volume495,955
Market Cap1.731B
Beta (5Y Monthly)1.21
PE Ratio (TTM)N/A
EPS (TTM)-2.47
Earnings DateMar 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est63.89
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • REGENXBIO to Participate in Upcoming Investor Conferences
    PR Newswire

    REGENXBIO to Participate in Upcoming Investor Conferences

    REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following March investor conferences, which will each be held in a virtual meeting format:

  • REGENXBIO to Host Conference Call on March 1 to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights
    PR Newswire

    REGENXBIO to Host Conference Call on March 1 to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights

    REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Monday, March 1, 2021, at 4:30 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2020, and recent operational highlights.

  • Benzinga

    Regenxbio Gene Therapy Shows Treatment Benefit In Wet AMD Study

    Regenxbio Inc (NASDAQ: RGNX) has reported additional interim data from Cohorts 4 and 5 of its Phase 1/2a trial evaluating RGX-314 for the treatment of wet age-related macular degeneration (wet AMD) and Cohort 3 of its Long-Term Follow-Up (LTFU) study. As of January 22, RGX-314 continued to be generally well-tolerated across all cohorts, with 20 serious adverse events (SAEs) reported in 13 patients, including one possibly drug-related SAE of a significant decrease in vision in Cohort 5. Patients in Cohorts 4 and 5 at 1.5 years after administration of RGX-314 demonstrated stable visual acuity and decreased central retinal thickness (CRT). A meaningful reduction in anti-VEGF treatment burden was observed in both Cohorts 4 and 5 compared to the mean annualized injection rate during the 12 months before RGX-314 administration. Patients in Cohort 4 and Cohort 5 received a mean of 4.4 injections and 1.7 injections over 1.5 years following administration of RGX-314, a 58.3% and 81.2% reduction in anti-VEGF treatment burden, respectively. Following the Phase 1/2a trial, patients can enroll in a long-term study to assess the safety and efficacy up to five years after RGX-314 administration. All six patients from Cohort 3 of the Phase 1/2a trial enrolled in the LTFU study and demonstrated a mean BCVA improvement of +12 letters from baseline at three years. Patients also demonstrated long-term reductions in anti-VEGF treatment burden over three years with a mean annualized rate of 2.4 anti-VEGF injections, a 66.7% reduction. Price Action: RGNX stock closed 0.8% lower at $46.96 on Friday. See more from BenzingaClick here for options trades from BenzingaExelixis' Cabozantinib Shows Overall Objective Response Rates of 38% In Genitourinary Tumor SettingsExelixis' Cabozantinib Data Shows Clinically Significant Benefit Versus Pfizer's Sutent, In A Type Of Kidney Cancer© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.